JP2015536301A5 - - Google Patents

Download PDF

Info

Publication number
JP2015536301A5
JP2015536301A5 JP2015535891A JP2015535891A JP2015536301A5 JP 2015536301 A5 JP2015536301 A5 JP 2015536301A5 JP 2015535891 A JP2015535891 A JP 2015535891A JP 2015535891 A JP2015535891 A JP 2015535891A JP 2015536301 A5 JP2015536301 A5 JP 2015536301A5
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
composition according
urine
measuring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015535891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015536301A (ja
JP6272880B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/063884 external-priority patent/WO2014058881A1/en
Publication of JP2015536301A publication Critical patent/JP2015536301A/ja
Publication of JP2015536301A5 publication Critical patent/JP2015536301A5/ja
Application granted granted Critical
Publication of JP6272880B2 publication Critical patent/JP6272880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015535891A 2012-10-09 2013-10-08 アルポート症候群の処置方法 Active JP6272880B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261711514P 2012-10-09 2012-10-09
US61/711,514 2012-10-09
US201361779137P 2013-03-13 2013-03-13
US61/779,137 2013-03-13
PCT/US2013/063884 WO2014058881A1 (en) 2012-10-09 2013-10-08 Methods for treatment of alport syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017253345A Division JP2018080190A (ja) 2012-10-09 2017-12-28 アルポート症候群の処置方法

Publications (3)

Publication Number Publication Date
JP2015536301A JP2015536301A (ja) 2015-12-21
JP2015536301A5 true JP2015536301A5 (enExample) 2016-12-01
JP6272880B2 JP6272880B2 (ja) 2018-01-31

Family

ID=49382663

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015535891A Active JP6272880B2 (ja) 2012-10-09 2013-10-08 アルポート症候群の処置方法
JP2017253345A Pending JP2018080190A (ja) 2012-10-09 2017-12-28 アルポート症候群の処置方法
JP2019189071A Pending JP2020073479A (ja) 2012-10-09 2019-10-16 アルポート症候群の処置方法
JP2022083586A Pending JP2022110140A (ja) 2012-10-09 2022-05-23 アルポート症候群の処置方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017253345A Pending JP2018080190A (ja) 2012-10-09 2017-12-28 アルポート症候群の処置方法
JP2019189071A Pending JP2020073479A (ja) 2012-10-09 2019-10-16 アルポート症候群の処置方法
JP2022083586A Pending JP2022110140A (ja) 2012-10-09 2022-05-23 アルポート症候群の処置方法

Country Status (34)

Country Link
US (8) US9012423B2 (enExample)
EP (2) EP2906698B1 (enExample)
JP (4) JP6272880B2 (enExample)
KR (4) KR20230136686A (enExample)
CN (1) CN104718295B (enExample)
AR (1) AR092940A1 (enExample)
AU (3) AU2013329427B2 (enExample)
BR (1) BR112015007709B1 (enExample)
CA (1) CA2885605A1 (enExample)
CL (1) CL2015000873A1 (enExample)
CR (1) CR20150236A (enExample)
CY (1) CY1122479T1 (enExample)
DK (1) DK2906698T3 (enExample)
EA (1) EA201590711A1 (enExample)
ES (2) ES2753174T3 (enExample)
HR (1) HRP20191948T1 (enExample)
HU (1) HUE045858T2 (enExample)
IL (2) IL237768B (enExample)
LT (1) LT2906698T (enExample)
MX (1) MX356340B (enExample)
MY (1) MY183921A (enExample)
NZ (1) NZ630596A (enExample)
PH (1) PH12015500781A1 (enExample)
PL (1) PL2906698T3 (enExample)
PT (1) PT2906698T (enExample)
RS (1) RS60014B1 (enExample)
SG (1) SG11201502748RA (enExample)
SI (1) SI2906698T1 (enExample)
TN (1) TN2015000099A1 (enExample)
TW (1) TWI641388B (enExample)
UA (1) UA116639C2 (enExample)
UY (1) UY35069A (enExample)
WO (1) WO2014058881A1 (enExample)
ZA (1) ZA201502087B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857878A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2012148952A1 (en) 2011-04-25 2012-11-01 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
EP2841579B1 (en) 2012-04-25 2018-10-10 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
EP3060664B1 (en) 2013-10-25 2021-07-07 Sanofi Microrna compounds and methods for modulating mir-21 activity
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CA2955481A1 (en) * 2014-07-25 2016-01-28 Goldfinch Biopharma, Inc. Collagen iv replacement
EP3182989B1 (en) 2014-08-21 2021-04-14 Stealth Biotherapeutics Corp Peptide d-arg-2',6'-dmt-lys-phe-nh2 for treating alport syndrome
EP3201339A4 (en) 2014-10-03 2018-09-19 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
AU2016334804B2 (en) 2015-10-09 2022-03-31 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
ES2882500T3 (es) 2015-12-14 2021-12-02 Cold Spring Harbor Laboratory Oligómeros antisentido para el tratamiento del síndrome de Dravet
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
AU2017356955B2 (en) 2016-11-08 2023-11-09 Reata Pharmaceuticals Holdings, LLC Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
CA3047894A1 (en) 2016-12-28 2018-07-05 Daiichi Sankyo Company, Limited Therapeutic drug for alport's syndrome
JP2020518633A (ja) * 2017-05-04 2020-06-25 サノフイＳａｎｏｆｉ アルポート症候群を治療するための方法
KR20200026878A (ko) 2017-06-06 2020-03-11 지머젠 인코포레이티드 균류 균주를 개량하기 위한 htp 게놈 공학 플랫폼
KR20200026874A (ko) 2017-06-06 2020-03-11 지머젠 인코포레이티드 대장균 개량을 위한 htp 게놈 공학 플랫폼
SI3673080T1 (sl) 2017-08-25 2024-03-29 Stoke Therapeutics, Inc. Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni
EP3700570B1 (en) 2017-10-23 2025-01-08 Stoke Therapeutics, Inc. Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
WO2019213525A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
SG11202104409YA (en) 2018-10-31 2021-05-28 Zymergen Inc Multiplexed deterministic assembly of dna libraries
KR20210134003A (ko) 2019-02-27 2021-11-08 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 안티센스 올리고머
US11053515B2 (en) 2019-03-08 2021-07-06 Zymergen Inc. Pooled genome editing in microbes
CA3129871A1 (en) 2019-03-08 2020-09-17 Zymergen Inc. Iterative genome editing in microbes
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
CA3176735A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
BR112022022889A2 (pt) 2020-05-11 2023-04-04 Stoke Therapeutics Inc Oligômeros antissentido de opa1 para tratamento de condições e doenças
US20260021079A1 (en) * 2022-05-09 2026-01-22 Calliditas Therapeutics Suisse Sa Nox inhibitors for use in the treatment of alport syndrome
WO2024238950A1 (en) * 2023-05-18 2024-11-21 Keros Therapeutics, Inc. Methods of using activin receptor type ii variants
WO2025110217A1 (ja) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 嚢胞性腎疾患の予防及び／又は治療剤

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ508317A (en) * 1998-05-22 2004-01-30 Boys Town Nat Res Hospital Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease
KR100574597B1 (ko) * 1998-05-22 2006-04-28 보이스 타운 내셔널 리서치 호스피탈 α1β1 인테그린 수용체 저해제 및 ＴＧＦ-β1 저해제의신장 질환의 치료용 용도
US20060008817A1 (en) 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
CA2462144C (en) 2001-09-28 2016-09-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Micro-rna molecules
US7585501B2 (en) * 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
EP2530157B1 (en) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US7585550B2 (en) 2004-02-02 2009-09-08 College Of William And Mary Process for modifying polymeric surfaces using deep UV irradiation
EP2290073A3 (en) 2004-05-28 2011-08-31 Asuragen, Inc. Methods and compositions involving microRNA
JP5192234B2 (ja) 2004-08-10 2013-05-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 化学修飾オリゴヌクレオチド
US20080187508A1 (en) 2004-09-08 2008-08-07 Boys Town National Research Hospital Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
CA2857878A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
US20070099196A1 (en) 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
DK1931780T3 (en) 2005-08-29 2016-01-25 Regulus Therapeutics Inc Antisense-forbindelser med forøget anti-microrna-aktivitet
US8129515B2 (en) 2006-01-27 2012-03-06 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
EP2261333B1 (en) 2006-04-03 2016-03-30 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
WO2008042973A2 (en) 2006-10-03 2008-04-10 Alnylam Pharmaceuticals, Inc. Lipid containing formulations
JP2010505427A (ja) 2006-10-09 2010-02-25 ジュリアス−マキシミリアンズ−ユニベルシタット ワーズブルグ 心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ）
WO2008073920A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
US8048998B2 (en) 2007-01-19 2011-11-01 Exiqon A/S Mediated cellular delivery of LNA oligonucleotides
WO2008151631A2 (en) 2007-06-15 2008-12-18 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
WO2008156868A2 (en) * 2007-06-20 2008-12-24 Baum Seth J Compositions and methods of treating chronic kidney disease
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
CA2704043C (en) 2007-10-29 2018-09-18 Rosetta Genomics Ltd. Targeting micrornas for the treatment of liver cancer
WO2009091972A2 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
WO2009099326A1 (en) 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
AU2010218147A1 (en) 2009-02-26 2011-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Dept. Of Health & Human Services MicroRNAs in never-smokers and related materials and methods
AU2010258875A1 (en) 2009-06-08 2012-01-19 Miragen Therapeutics Chemical modification motifs for miRNA inhibitors and mimetics
WO2011126842A2 (en) * 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
WO2012148952A1 (en) 2011-04-25 2012-11-01 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
EP2841579B1 (en) 2012-04-25 2018-10-10 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
EP2900822B1 (en) 2012-09-26 2021-11-24 Guangdong Maijinjia Biotechnology Co., Ltd Oligomers with improved off-target profile
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Similar Documents

Publication Publication Date Title
JP2022110140A (ja) アルポート症候群の処置方法
JP2018528945A5 (enExample)
HRP20210616T1 (hr) Spojevi mikrornk i postupci za moduliranje aktivnosti mir-21
JP2014518619A5 (enExample)
JP2018530325A (ja) アンジオテンシノーゲンの発現を調節するための化合物及び方法
JP2017500031A5 (enExample)
RU2018108206A (ru) Способы лечения поликистозной болезни почек
ES2988845T3 (es) Procedimientos predictivos y diagnósticos para cáncer de próstata
TW202300647A (zh) 用於治療多囊腎病之組成物
JP2019536803A5 (enExample)
Roberts et al. Adenosine receptor expression in the development of renal fibrosis following ischemic injury
CN119137272A (zh) 血管紧张素原调节组合物和其使用方法
KR20190093207A (ko) 다낭성 신장 질환의 치료 방법
CN102716123B (zh) 一种用于治疗IgA肾病复方制剂
JP2020518633A5 (enExample)
WO2023122656A1 (en) Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors
RU2019139261A (ru) Способы лечения синдрома альпорта
JP2008540448A (ja) 糖尿病性腎症の治療において、スロデキシド及び血圧低下薬を用いた併用療法
Tan et al. Protective effects of FR167653 on chronic allograft nephropathy by inhibiting p38 MAPK in rats
WO2024102913A1 (en) Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors
TH1901003360A (th) โอลิโกนิวคลีโอไทด์สำหรับใช้ในการบำบัดโรคถุงน้ำในไต
HK40014087B (en) Methods for treatment of polycystic kidney disease